InsidersTradesSigma
한올바이오파마 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 한올바이오파마 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 한올바이오파마 has logged 6 reports. Market capitalisation: €2,873.5bn. The latest transaction was filed on 2 July 2026 (Other). Among the most active insiders: 국민연금공단. All data is accessible without an account.
6
Insider Decl.
0
Thresholds
€19m
4 ops.
Buy Volume
·
0 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,427 of 26,270 companies
35.5
score / 100
Value33
Quality38
FCF yld-0.6%
Earn yld-0.2%
EV/EBITDA·
ROE-3.2%
Gross mgn52%
Net mgn-3.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2026
Declarations6 total
6 of 6 declarations
About 한올바이오파마
Hanall Biopharma is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and ophthalmic disorders. It is listed on the XKRX market.